Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy by M..C. Pera et al.
Functional Neurology 2015; 30(3): 173-179 173
Maria Carmela Pera, MDa,b
Giovanna Randazzo, MDa,b
Silvia Masnada, MDa,b
Serena Donetti Dontin, MDa,b
Valentina De Giorgis, MDb
Umberto Balottin, MDa,b
Pierangelo Veggiotti, MDa,b
a Child Neuropsychiatry Unit, C. Mondino National
Neurological Institute, Pavia, Italy
b Department of Brain and Behavior, University of
Pavia, Italy
Correspondence to: Pierangelo Veggiotti
E-mail: pveggiot@unipv.it
Summary
The aim of this retrospective study of children affect-
ed by epileptic encephalopathy was to evaluate
seizure frequency, electroencephalographic pattern
and neuropsychological status, before and after
intravenous methylprednisolone therapy.
Eleven children with epileptic encephalopathy were
administered one cycle of intravenous methylpred-
nisolone (15-30 mg/kg/day for three consecutive
days, once a month for four months) in addition to
constant dosages of their regular antiepileptic
drugs.
The treatment resulted in statistically significant
reductions of generalized slow spike-and-wave dis-
charges (p<0.0028) and seizure frequency (p<0.013),
which persisted even after methylprednisolone pulse
therapy was stopped. A globally positive outcome
was noted in 9/11 patients (81.8%). This methylpred-
nisolone treatment regimen did not cause significant
or persistent adverse effects.
We suggest that children with epileptic encephalopa-
thy without an underlying structural lesion could be
the best candidates for intravenous methylpred-
nisolone pulse therapy.
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Introduction
The epileptic encephalopathies are a group of conditions
in which the epileptic activity itself – ictal or interictal, clin-
ical or electroencephalographic – contributes to a picture
of severe cognitive and behavioral impairments, which
are beyond what might be expected from the underlying
etiology alone (Wirrell et al., 2005; Berg et al., 2010).
This diagnostic category was first introduced in 2001 in
the Terminology and Classification Report of the
International League Against Epilepsy (ILAE), and for-
mally recognized in the 2006 ILAE Report. The epileptic
encephalopathies are age-dependent syndromes that
usually begin in infancy and early childhood (Wirrell et
al., 2005), and they account for about 40% of all epilep-
sies occurring in the first three years of life (Guerrini,
2006). Some of these syndromes have a known etiology
(e.g., genetic or metabolic/structural), but in most cases
the underlying cause is unknown. The epileptic
encephalopathies are typically drug resistant; polythera-
py leads to seizure freedom in less than 5-10% of
patients (Raspall-Chaure et al., 2008; Parisi et al., 2010).
Consequently, there is a need to integrate new and spe-
cific therapeutic approaches, such as corticosteroid ther-
apy. The corticosteroids most widely used in childhood
encephalopathies are adrenocorticotropic hormone,
hydrocortisone, prednisone and methylprednisolone. A
good response to these drugs has been reported in var-
ious studies and case reports (Tsuru et al., 2000; Gupta
and Appleton, 2005; Okuyaz et al., 2005; Gallagher et
al., 2006; Inutsuka et al., 2006; Urbain et al., 2011;
Heyman et al., 2012), as well as in the extended study
conducted by Buzatu et al. (2009). However, the avail-
able evidence is limited, since it comes from uncontrolled
trials and case reports and there is, as yet, no consensus
on treatment dosages and durations (Veggiotti et al.,
2012). Over the past two decades, high-dose intra-
venous corticosteroid pulse therapy (an approach
already used to treat several neurological syndromes
such as multiple sclerosis) has been used in various
studies in the field of epilepsy in order to avoid the devel-
opment of side effects and maintain long-term efficacy
(Aykut-Bingol et al., 1996; Tsuru et al., 2000; Okuyaz et
al., 2005; Sevilla-Castillo et al., 2009; Lichtenfeld et al.,
2010; Mytinger et al., 2010; Heyman et al., 2012;
Almaabdi et al., 2014). Administered according to differ-
ent regimens (dosages ranging from 15 mg/kg/day for
three or five days to 30 mg/kg/day for two or three days),
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repeated at different intervals (weekly or monthly)
(Donetti Dontin et al., 2013), it has been shown to be
successful in different disorders (Landau-Kleffner syn-
drome, absence seizures, infantile spasms, epileptic
encephalopathies in general).
The aim of this retrospective study of children with
epileptic encephalopathy was to evaluate seizure fre-
quency, electroencephalographic pattern and neu-
ropsychological status, before and after intravenous
methylprednisolone therapy.
Materials and methods
This case series consists of 11 children with epileptic
encephalopathy (5 females and 6 males), studied at
the Child Neuropsychiatry Unit, C. Mondino National
Neurological Institute, University of Pavia, between
February 2013 and May 2014. All the included
patients met the ILAE diagnostic criteria for epileptic
encephalopathy (Berg et al., 2010). Five of them
(45.5%) had received a diagnosis of Lennox-Gastaut
syndrome (LGS) and six (54.5%) a diagnosis of elec-
trical status epilepticus during slow-wave sleep
(ESES) according to the ILAE criteria (Berg et al.,
2010). Their charts were retrospectively reviewed.
Seizure frequency, before and after therapy, was
assessed on the basis of parents’ reports (Tables I
and II). Applying a neurocognitive assessment proto-
col already used in similar studies (Veggiotti et al.,
2012; Pera et al., 2013), all the patients underwent
serial neurological examinations, wake and sleep
electroencephalogram (EEG), and at least one noctur-
nal polygraphic monitoring. Serial cognitive assess-
ments were also performed using the standardized
Wechsler scales or Raven’s Progressive Matrices
according to the child’s age and degree of collabora-
tion. If a child was unable to perform any of the stan-
dardized tests, clinical observation of that child’s
behavior was recorded instead. The evaluation also
included: blood pressure, body weight, complete
blood count, glycemia, liver function and serum elec-
trolytes. Intravenous methylprednisolone was given to
the patients in addition to constant dosages of their
regular antiepileptic drugs (AEDs). One cycle of pulse
therapy consisted of intravenous methylprednisolone
administered at 15-30 mg/kg/day for three consecu-
tive days, once a month, for four months (12 infusions
in total). Written informed consent was obtained from
the children’s parents or legal guardians.
The patients were considered responders when seizure
frequency after the pulse therapy was reduced by at
least 50%. Descriptive analyses were performed and
the variables were examined using chi-square statistics
to identify the magnitude of any significant associations.
Results
Eleven children with drug-resistant epilepsy (six
females, 54.5%; five males, 45.5%) comprised the
study group. Five of them (45.5%) had received a
diagnosis of LGS (3 males; 2 females) and six (54.5%)
a diagnosis of ESES (3 males; 3 females). At the start
of the study they ranged in age from 4.3 years to 16.1
years (mean age 9.1 years). Their mean age at onset
of seizures was 47.3 months (range: 0.8-96 months).
In the LGS group, two patients (40%, both males) had
a structural etiology, whereas the etiology was
unknown in the other three (60%, 2 females and 1
male) (Table I). In the ESES group, two patients
(33.3%, 1 female and 1 male) had a structural etiolo-
gy, and four patients (66.6%, 2 females and 2 males)
an unknown etiology (Table II). Overall, four patients
(36.4%) presented underlying brain damage prior to
the onset of epileptic encephalopathy and seven
patients (63.7%) had no cerebral lesion before dis-
ease onset.
In the LGS group, three patients (60%) had epileptic
spasms, one (20%) had generalized myoclonic
seizures, and one (20%) had generalized tonic-clonic
seizures. In the ESES group, four patients (66.6%)
had focal seizures (complex partial in three and focal
motor in one) and two patients (33.3%) had atypical
absence seizures.
The frequency of epileptic seizures during the three
months before the start of the pulse therapy was more
than 50 seizures/month in five (45.5%) patients (4
LGS, 1 ESES), 20-50/month in one (9.1%) patient
with LGS, 11-20/month in two patients (18.2%) with
ESES, and less than one seizure/month in three
patients (27.3%) with ESES. At the onset of seizures,
two patients in the LGS group had a global develop-
mental delay with aphasia (18.2%) and two patients (1
LGS, 1 ESES) had only a motor delay (18.2%). The
remaining patients showed no developmental delay.
In six patients (54.5%) the EEG prior to starting the
methylprednisolone therapy showed continuous
epileptiform activity occupying more than 85% of non-
rapid eye movement (NREM) sleep and persisting for
a minimum of three electroencephalographic record-
ings over a period of at least one month; these
patients therefore met the diagnostic criteria for con-
tinuous spikes and waves during NREM sleep. In the
other five patients electroencephalographic studies
showed abnormal generalized spike-slow wave dis-
charges (SWDs) at <2.5 Hz. These occur during both
wakefulness and sleep and can show both interictal
and ictal patterns. Bursts of fast activity (rhythmic
rapid spikes at 10-20 Hz) during sleep are also char-
acteristic.
At the beginning of the pulse therapy, six (54.5%)
patients (4 LGS, 2 ESES) were taking three or more
AEDs and five (45.5%) patients (1 LGS, 4 ESES) one
or two AEDs. It is to be noted that nine patients
(81.8%) had, in the course of their disease, tried more
than four AEDs. In addition, one patient (2/F) had
been implanted with a vagal nerve stimulator since
April 2007 and another (3/F) had tried a ketogenic diet
for two months. During a brief hospitalization (three
days), intravenous methylprednisolone pulse therapy
was added to the patients’ ongoing AED therapy,
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which ranged from one to six AEDs. All the patients
completed one cycle of pulse therapy, after which they
were monitored for a mean of 14.1 months (range: 8-
16 months) to evaluate electroencephalographic mod-
ifications, seizure frequency, global outcome (behav-
ior, neurological examination, cognitive abilities) and
possible side effects. The frequency of epileptic
seizures before the pulse therapy ranged from 1 to 90
per month, with a mean of 47.5 seizures/month. At fol-
low-up it ranged from 0 to 80 seizures/month with a
mean of 21.2 (p<0.013). In detail, more than 50
seizures/month were recorded in 1/11 patient (9.1%),
20-50/month in 4/11 patients (36.4%), less than
one/month in 2/11 patients (18.1%), and no seizures
in 4/11 patients (36.4%). Eight patients (72.7%)
responded to the cycle of pulse therapy (showing an
at least 50% reduction of seizure frequency). The
above results show that methylprednisolone pulse
therapy significantly reduced seizure frequency and
that this significant reduction persisted after methyl-
Steroid pulse therapy in epilepsy
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Table I - LGS group: clinical, therapeutic and electroencephalographic data. 
Case/sex 1/M 2/F 3/F 4/M 5/M
Etiology Structural Unknown Unknown Unknown Structural
(bilateral atrophy) (PVL)
Age at onset 52 3 3 32 23
of seizures
(months)
Age at start 143 193 177 51 56
of PT cycle 
(months)
Type of seizures Spasms Spasms Spasms Generalized GTCS
(myoclonic-atonic)
Neurological Motor delay Motor delay Normal Normal CP
problems before and aphasia and aphasia
epilepsy onset
Previous AEDs VPA, LTG, NZP, VPA, NZP, RFN, VPA, PB, VGB, CLB, VPA, LTG, VPA, PB, TPM,
HC, RFN PB, VGB, LTG, LTG, LEV, CBZ, LEV, RFN, ACTH RFN, ZNS, 
FBM, CBZ, CLB, FBM, TPM, HC, CLB, ACTH
CZP, ESM, TPM, LCM, CLB
LEV, ACTH
AEDs at VPA, LTG, NZP, VPA, NZP, RFN VPA, LEV, TPM, VPA, LEV PB, RFN,
start of PT RFN FBM, CLB, LCM ZNS, CLB
EEG before PT Awake and sleep: Awake: Awake and sleep: Awake: very Awake and
very frequent very frequent SDs (frontal- frequent SWDs sleep: bilateral
multifocal SWDs multifocal SWDs parietal right>left) (>80%) (bilateral) slow activity




EEG after PT Awake and sleep: Awake: Awake and sleep: Awake and sleep: No change
modest reduction modest reduction moderate dramatic reduction
of multifocal of multifocal amplitude of SDs of SWDs (5%)





Seizure >50 >50 >50 >50 20-50
frequency seizures/month seizures/month seizures/month seizures/month seizures/month
before PT
Seizure 20-50 20-50 20-50 Seizure free No change
frequency seizures/month seizures/month seizures/month
after PT
Abbreviations: M=male; F=female; LGS=Lennox-Gastaut syndrome; EEG=electroencephalogram; PVL=periventicular leukomalacia; GTCS=generalized
tonic-clonic seizures; CP=cerebral palsy; AEDs=antiepileptic drugs; PT=pulse therapy; SWDs=spike-slow wave discharges; SDs=spike discharges;
VPA=valproic acid; NZP=nitrazepam; HC=hydrocortisone; PB=phenobarbital; VGB=vigabatrin; LTG=lamotrigine; FBM=felbamate; CBZ=carbamazepine;
CLB=clobazam; CZP=clonazepam; ESM=ethosuximide; TPM=topiramate; LEV=levetiracetam; ACTH=adrenocorticotropic hormone; LCM=lacosamide;
RFN=rufinamide; ZNS=zonisamide.
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Table II - ESES group: clinical, therapeutic and electroencephalographic data.
Case/sex 6/F 7/M 8/F 9/F 10/M 11/M
Etiology Structural Unknown Unknown Unknown Structural Structural
(hydrocephaly) (cavernous (cavernous
angioma) angioma)
Age at onset 36 96 87 93 0.8 94
of seizures
(months)
Age at start 83 105 124 107 105 95
of PT cycle
(months)
Type of Complex AA Complex Complex Focal AA
seizures partial partial partial motor




Previous VPA, LEV, TPM, CLB, ESM LEV, VPA, CLB, VPA, VPA, LEV, VPA, NZP,
AEDs ESM, LTG, NZP, ESM, CLB LEV CLB, PB, HC, ESM, STM
CLB, DZP, HC, STM, ESM
STM 
AEDs at VPA, ESM, CLB CLB, ESM VPA, ESM, CLB LEV ESM, CLB VPA, STM
start of PT
EEG Awake: SWDs Awake: Awake: Awake: Awake: Awake: 
before PT (central, left>right) rare SWDs frequent SWDs rare SDs SWDs frequent SDs
Sleep: Sleep: (temporal (bilateral) (frontal, (bilateral),
CSWS (85%) CSWS (90%) bilateral) Sleep: right>left) slow activity
Sleep: CSWS (85%) Sleep: on right;




EEG No change Awake: Awake: Awake: No change Awake:
after PT no change rare SWDs reduction marked 
Sleep: (temporal of SDs reduction of
dramatic bilateral) Sleep: SDs and
reduction Sleep: dramatic SWDs
of SWDs dramatic reduction Sleep: 
(10%) reduction of of SWDs dramatic
SWDs (20%) (10%) reduction of
SWDs (10%)
Seizure >50 <1 11-20 <1 <1 11-20
frequency seizures/month seizure/month seizures/month seizure/month seizure/month seizures/month
before PT
Seizure No change Seizure free <1 Seizure free No change Seizure free
frequency seizure/month
after PT
Abbreviations: M=male; F=female; AA=atypical absence seizure; AEDs=antiepileptic drugs; PT=pulse therapy; SWDs=spike-slow wave discharges;
SDs=spike discharges; CSWS=continuous spike-and-waves during slow-wave sleep; VPA=valproic acid; NZP=nitrazepam; HC=hydrocortisone; PB=phe-
nobarbital; LTG=lamotrigine; CLB=clobazam; ESM=ethosuximide; TPM=topiramate; LEV=levetiracetam; DZP=diazepam; STM=sulthiame.
prednisolone administration was stopped. At the end
of the follow-up, electroencephalographic abnormali-
ties were reduced in 8/11 patients (72.7%). In particu-
lar in the ESES group, 4/6 patients (66.7%) no longer
met the criteria for continuous spikes and waves dur-
ing NREM sleep. In these four patients, the mean
reduction of SWDs was about 78.8%. The other 2/6
patients (33.3%), who showed no changes in SWDs,
have a structural etiology underlying their epilepsy. In
the LGS group, 4/5 patients (80%) showed improve-
ments of their electroencephalographic abnormalities
with an approximately 34% mean reduction in SWDs.
The only patient (20%) in the LGS group whose SWDs
showed no changes is affected by symptomatic
epilepsy. These results show that the reduction in
SWDs induced by the pulse therapy, which persisted
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even after the end of this therapy, was statistically sig-
nificant (p<0.0028).
A positive global outcome was noted in 9/11 patients
(81.8%). In particular, improvements were found in
cognitive function (a gain of between 2 and 15 IQ
points, mean 8.8 points) in five patients (45.5%), in
attention in 2/11 patients (18.2%), in behavior in 2/11
patients (18.2%), and in language in 3/11 patients
(27.3%) (Table III).
No significant or persistent side effects were noted, in
particular only a modest transient hyperglycemia in
the 24 hours after infusion in 1/11 patient (9.1%) and
a modest weight gain in 1/11 patient (9.1%) (this
patient had introduced valproic acid therapy one
month before the start of the pulse therapy).
Discussion
The results of this study suggest that the intravenous
methylprednisolone pulse therapy regimen described
herein induces a statistically significant reduction
(p<0.013) of seizure frequency in children with epilep-
tic encephalopathy. The frequency of epileptic seizures
was reduced by more than 50% in 8/11 patients
(72.7%) at the end of the cycle, and in all of them this
reduction was sustained even after methylpred-
nisolone therapy was stopped, confirming the efficacy
of corticosteroid therapy in reducing seizure frequency.
Four of the eight responders became seizure free: one
from the LGS group, who presented with myoclonic
atonic seizures, and three from the ESES group. The
seizure frequency reduction was clinically more signif-
icant in the LGS patients, whose seizure frequency
was considerably higher than in the ESES patients.
The three non-responders all had a structural etiology,
suggesting that this treatment is less effective in this
group of patients; given the small size of the sample,
further studies are needed to confirm this finding in a
larger cohort of children with epileptic encephalopathy.
Eight patients (8/11, 72.7%) showed a dramatic
improvement on EEG with a statistically significant
reduction of abnormal SWDs (p<0.0028). The reduc-
tion of EEG abnormalities was most marked in
patients with ESES, but EEG improvements were also
observed in LGS patients with a clinical response.
Analyzing the results of the standardized tests and/or
caregivers’ reports on attention and behavior, the
global outcome was positive in 9/11 patients (81.8%).
Even though the severity of the impairment in some of
the children meant that this result could not be demon-
strated through standardized tests in all the patients, it
is nevertheless an important finding since a global
improvement increases the quality of life both of affec-
ted children and their families. This positive global out-
come was associated with reductions in both seizure
frequency and interictal EEG abnormalities.
Although the Cochrane review on corticosteroids for
childhood epilepsy other than epileptic spasms found
no evidence for their efficacy or safety in treating
childhood epilepsies (Gayatri et al., 2007), our results,
along with those of other case reports and retrospec-
tive studies on this therapeutic option (Aykut-Bingol et
al., 1996; Tsuru et al., 2000; Okuyaz et al., 2005;
Steroid pulse therapy in epilepsy
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Table III - Clinical data and outcome.
Case/ Epilepsy Neurological problems Neurological problems Outcome after PT
sex syndrome before epilepsy at the start of PT
1/M LGS Motor delay and aphasia Severe mental retardation (TIQ <20) Behavior improved
2/F LGS Motor delay and aphasia Severe mental retardation (TIQ <20) Minimum IQ improvement 
(TIQ 31)
3/F LGS Normal Severe mental retardation (TIQ 35) Attention improved
4/M LGS Normal Psychomotor delay (DQ 40) Language and attention 
significantly improved
5/M LGS CP Severe mental retardation (TIQ <20) Psychomotor agitation 
reduced
6/F ESES Minimum motor development Severe mental retardation (TIQ 38) No change
7/M ESES Normal Mild mental retardation (TIQ 68) School-learning ability and 
minimum IQ improved 
(TIQ 70)
8/F ESES Normal Mild mental retardation (TIQ 63) Borderline mental 
impairment (TIQ 75)
9/F ESES Normal Normal IQ (TIQ 86) Normal IQ (TIQ 90)
10/M ESES Normal Severe mental retardation (TIQ 20) No change
11/M ESES Normal Aphasia and moderate performance Language gain (about 20 
impairment (PIQ 50) words) and performance
improvement (PIQ 65)
Abbreviations: M=male; F=female; PT=pulse therapy; LGS=Lennox-Gastaut syndrome; ESES=electrical status epilepticus during slow-wave sleep;
CP=cerebral palsy; IQ=intelligence quotient; TIQ=total intelligence quotient; PIQ=performance intelligence quotient; DQ=developmental quotient.
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Sevilla-Castillo et al., 2009; Lichtenfeld et al., 2010;
Heyman et al., 2012), confirm the usefulness of this
approach. In particular, Heyman et al. (2012) found
clinical and electroencephalographic improvements in
more than 50% of patients; both Aykut-Bingol et al.
(1996) and Tsuru et al. (2000) reported suppression of
EEG abnormalities and language improvement in
Landau-Kleffner patients. The same results were
found by Okuyaz et al. (2005) in their patient with con-
tinuous spike-and-waves during slow-wave sleep
(CSWS) and partial epilepsy. Sevilla-Castillo et al.
(2009) administered pulse therapy to 14 patients and
reported a significant reduction in seizure frequency
(>50%) in 12 of them; the two non-responders had a
structural etiology. Lichtenfeld et al. (2010) reported a
significant reduction in EEG abnormalities in a girl pre-
senting with absence seizures treated with a pulse
therapy regimen. Although literature reports have indi-
cated a high relapse rate in patients with epileptic
encephalopathy (44-70% within 3-6 months) (Sinclair,
2003; Gupta and Appleton, 2005; Verhelst et al., 2005;
Okumura et al., 2006; You et al., 2008), this was not
confirmed by the present study.
There are several theories regarding the mechanism
of action of corticosteroids in epilepsy. Adrenocor -
ticotropic hormone can affect infantile spasms through
g-aminobutyric acid [GABA(A)] receptor-mediated
anticonvulsant effects or systematically through the
hypothalamic-pituitary-adrenal axis, thus suppressing
corticotropin-releasing hormone and decreasing neu-
ronal excitability.. These mechanisms may also be
related to the effects of steroids on absence seizures
and LGS. Possible neuromodulatory effects may
include correction of deficient or dysfunctional
enzymes, changes in intracellular-extracellular elec-
trolyte ratios, correction of low intracellular glucose,
reduction in cerebral water content, and modulation of
intracellular adenosine and neurosteroid production
(Marchi et al., 2011).
The immunomodulatory or anti-inflammatory properties
of corticosteroids have been postulated to be responsi-
ble for the action of these drugs in Landau-Kleffner syn-
drome and ESES. Since the anticonvulsant effect of
corticosteroids persists after drug discontinuation, it
has been suggested that in addition to allowing acute
seizure control, corticosteroids may reset a deranged
cerebral homeostatic mechanism, thus increasing
refractoriness to seizure recurrence (Vezzani and
Granata, 2005; Özkara and Vigevano, 2011).
A major concern related to corticosteroids, especially
in children and adolescents, is the possible develop-
ment of side effects. The most frequent ones are
excessive weight gain, hyperphagia, water retention
with edema, Cushingoid appearance, hypertension,
behavioral disturbances, increased infection suscepti-
bility, leukopenia, electrolyte disturbances, hyper-
glycemia, glycosuria, impaired glucose tolerance,
frank diabetes and sleep disorders. Furthermore,
long-term side effects such as hypothalamus-pituitary
axis suppression, psychosis, osteoporosis, nephrocal-
cinosis, brain atrophy, cataracts and, in children,
growth retardation, have also been reported (Gupta
and Appleton, 2005; Malphrus and Wilfong, 2007).
Since methylprednisolone treatment did not cause sig-
nificant or persistent adverse effects in our case
series [1/11 patient (9.1%) showed a modest transient
hyperglycemia in the 24 hours after infusions; 1/11
patient (9.1%) a modest weight gain], methylpred-
nisolone treatment, administered according to the reg-
imen herein described, seems to be safe. Taking into
account the negative prognosis of severe childhood
epilepsies, pulse therapy may be a safe and effective
therapeutic option for children who show resistance to
conventional AEDs. It is therefore important to identify
a priori those who are more likely to benefit from the
treatment and to avoid unnecessary exposure of other
patients. We suggest that children with epileptic
encephalopathy without an underlying structural
lesion could be the best candidates for intravenous
methylprednisolone pulse therapy.
Larger randomized controlled studies in children are
needed to establish the long-term efficacy and safety
of this treatment.
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